Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Bullboard Posts
Comment by silvarlineon Apr 22, 2013 10:43pm
111 Views
Post# 21286616

RE: RE: RE: RE: RE: mbx

RE: RE: RE: RE: RE: mbx

My recent conversations with Vaughn confirm your assessment and my thoughts, exactly.

Aswell,  we discussed the status of Novartis challenge and vaccine production.  Very enlightening.  

I came away knowing that our patent is extremely valuable to companies like Novartis who make vaccines.  When our patent is incorporated into their manufacturing processes the end result is much larger yields in vaccine production using a fraction of the raw materials (eggs) needed. i am sure Novartis (and others) would love to utilize this technology (if they haven't already ... ??) without having to deal with patent infringement.  The dollars in compensation to MBX WILL amount to big $$$$!   PerhapsNovartis and others will decide to settlement outside the courts.  I guess anything is possible.  One thing is for sure, Vaughn is making it a priority to ensure we get the most value out of this technology.  

I don't think Novartis has a "snowballs chance in hell" in succeeding with their opposition to our patent claims.  It's interesting to note that we were granted a patent in the United States and one patent in Europe. As well, while the patent process was pending there was no one that opposed or raised issue with our claims, not anyone. 

Anyway, the process has a mind of it's own and it will take time to resolve and come to a decision.  We need to be patient and let it take it course.  There's not much new on the European Patent Register but alot going on behind the scenes.

Anyway that's my rant for now ...

Buy, hold and accumulate.

 

 

Bullboard Posts